目的：探讨检测非小细胞肺癌组织中 ERCC1、BRCA1、RRM1的蛋白表达在化疗方案选择中的临床意义。方法：选取确诊非小细胞肺癌患者120例，随机分为两组。常规化疗组（60例）给予吉西他滨／紫杉醇＋顺铂化疗；实验组（60例）：化疗前检测 ERCC1、RRM1、BRCA1蛋白的表达，选用敏感的化疗药物治疗。比较两组的疗效、无疾病进展时间和生存期。结果：实验组中 ERCC 1蛋 白 和 BRCA 1蛋 白 表 达 阳 性 率 为28．33％，RRM1蛋白表达阳性率为51．67％。治疗两周期后评价常规化疗组和实验组的化疗客观缓解率分别是35．00％（21／60），43．33％（26／60），无统计学差异（P ＞0．05）。两组无疾病进展平均时间、中位时间分别为实验组6．653个月、4．8个月；常规化疗组4．35个月、3．5个月，有统计学意义（P ＜0．05）。生存分析两组比较差异无统计学意义（P ＞0．05）。结论：检测 ERCC1蛋白、BRCA1蛋白、RRM1蛋白的表达选择化疗方案使非小细胞肺癌患者在临床化疗中获益，可以延长无疾病进展时间。%Objective:To dissuss the clinical significance of protein expression level of excision repair cross com-plementing 1 (ERCC1 ),breast cancer susceptibility gene 1 (BRCA1 )and ribonucleotide reductase subunit M1 (RRM1)from lung cancer tissue in chemotherapy plan for patients with non -small cell lung cancer(NSCLC). Methods:Totally 120 patients with NSCLC were selected and randomly divided into the conventional chemotherapy group(n =60)and the experimental group(n =60)according to different chemotherapies.The conventional chemo-therapy group was treated by gemcitabine or paclitaxel combined with cisplation.The experimental group guided pa-tients to choose chemotherapeutics with sensitivity by detecting the protein expression level ofERCC1,BRCA1,RRM1 .The curative effect,progression -free -time and the survival time for two years in the two groups after chemotherapy were compared.Results:In the experimental group,the protein expression of ERCC 1 ,BRCA 1 and RRM1 were 28.33%,28.33% and 51.67%.There was no statistically significant difference between the two groups on effective rate and the survival on 1 year and 2 years after chemotherapy.The mean and median time to progression -free -time were respectively 6.653 months,4.8 months in the experimental group and 4.35 months,3.5 months in the conven-tional chemotherapy group,the difference had statistical significance(P <0.05).Conclusion:The detection of ER-CC1,BRCA1 and RRM1 protein expression benefits the patients with non -small cell lung cancer which prolongs the progression -free -time.
展开▼
